The Australian New Zealand Spontaneous Coronary Artery Dissection (ANZ-SCAD) Registry

This project will pilot the first ever Australian-New Zealand Spontaneous Coronary Artery Dissection (ANZ-SCAD) Registry. Patients will be recruited from each individual site with their baseline clinical data entered locally by a study coordinator and captured onto an online centralised database. Baseline data includes background medical history (including known pre-disposing genetic conditions), cardiovascular risk factors, medications at baseline and on discharge, presentation, triggers, investigations (including CTCA and CMR), management (including revascularisation) and in-hospital outcomes. In-hospital pathology results will be collected including serum creatinine and electrolytes, liver function, full blood count, high sensitivity C-reactive protein (hs-CRP), fasting lipids (TC, LDL, HDL, triglycerides) and diabetic profiles will be collected for all patients. For retrospective patients, data will be collected from their respective treating hospital from 1st Mar 2011 to date. There are 18 recruiting sites in total across Australia and New Zealand. Prospective patients will be recruited ongoing from their treating hospital upon admission with a diagnosis of SCAD. Follow up will be performed at 30days, 1 year and early there after for upto 5years. Questionnaire will be sent directly to participants to collect their pre- and post-SCAD family and medical history, exercise, stress, quality of life and medication use data. Retrospectively recruited patients will not have ongoing follow up, with the date of last follow up or death taken from the available medical records at the time of recruitment. In hospital scans, angiograms and procedures data will be collected for all participants. As this is an observational study, all data will be collected either from participants medical records or questionnaires. No additional tests and cardiac scans for this study purpose will be required. The follow-up will be largely electronic by participants receiving an email link to a secure survey generated by the REDCap database that assess self-reported outcomes. Telephone contact will be performed when required by each site if participants are unable to complete the survey. This will be with the use of telephone interpreters as needed for those of Non-English speaking backgrounds, and hospital/medical records obtained to clarify diagnoses, as required. Thirty day follow up will include a Quality of Life (QoL) assessment using the EQ-5D questionnaire. A Seattle Angina Questionnaire will be used at 1 and 2 year follow-ups. Clinical outcomes will be total and cardiac mortality, SCAD recurrence, major adverse cardiovascular events (MACE) and major adverse cardiac and cerebrovascular events (MACCE). Participants recruited retrospectively will not be consented. Waiver of consent has been obtained from relevant ethics committee. Participants will not be contacted. Patients with a clinical diagnosis of SCAD based on presentation features and confirmed on coronary angiography is eligible for this study. Coronary angiogram and procedure reports will be collected from participants electronic medical records